Troglitazone inhibits voltage-dependent calcium currents in guinea pig cardiac myocytes

Circulation

Volumn 99, Issue 22, 1999, Pages 2942-2950

  Nakajima, Toshiaki ^a,c   Iwasawa, Kuniaki ^a   Oonuma, Hitoshi ^a   Imuta, Hiroyuki ^a   Hazama, Hisanori ^a   Asano, Michiko ^a   Morita, Toshihiro ^a   Nakamura, Fumitaka ^a   Suzuki, Jun Ichi ^a   Suzuki, Seiji ^b   Kawakami, Yasushi ^b   Omata, Masao ^a   Okuda, Yukichi ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Calcium; Cardiomyopathy; Diabetes; Isoproterenol; Myocytes; Troglitazone

Indexed keywords

CALCIUM ION; ISOPRENALINE; NIFEDIPINE; TROGLITAZONE; VERAPAMIL;

ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM CURRENT; CARDIOMYOPATHY; CELL MEMBRANE TRANSPORT; CHANNEL GATING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; GUINEA PIG; HEART CELL CULTURE; HEART MUSCLE FIBER MEMBRANE CONDUCTANCE; NONHUMAN; PRIORITY JOURNAL; TRANSPORT KINETICS;

EID: 0033536075     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.22.2942     Document Type: Article

References (43)

1. Regan TJ, Ettinger PO, Khan MI, Jesrani MU, Lyons MM, Oldewurtel HA, Weber M. Altered myocardial function and metabolism in chronic diabetes mellitus without ischemia in dogs. Circ Res. 1973;35:222-237.
2. Hamby RI, Zoneraich S, Sherman S. Diabetic cardiomyopathy. JAMA. 1974;229:1749-1754.
3. Garber DW, Neely JR. Decreased myocardial function and myosin ATPase in hearts from diabetic rats. Am J Physiol. 1983;244: H586-H591.
4. Galderisi M, Anderson KM, Wilson PWF, Levy D. Echocardiographic evidence for existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol. 1991;68:85-89.
5. Penpargkul S, Fein F, Sonnenblick EH, Scheuer J. Depressed cardiac sarcoplasmic reticular function from diabetic rats. J Mol Cell Cardiol. 1981;13:303-309.
6. + pump concentration in skeletal muscle, heart ventricular muscle, and peripheral nerves of rat. Diabetes. 1987;36:842-848.
7. 2+ transport in streptozotocin-induced diabetic cardiomyopathy in rats. Am J Physiol. 1987;253:E202-E207.
8. Pierce GN, Dhalla NS. Heart mitochondrial function in chronic experimental diabetes in rats. Can J Cardiol. 1985;1:48-54.
9. 2+ channel. Cardiovasc Res. 1990;24: 381-389.
10. Magyar J, Rusznak Z, Szentesi P, Szucs G, Kovacs L. Action potentials and potassium currents in rat ventricular muscle during experimental diabetes. J Mol Cell Cardiol. 1992;24:841-853.
11. Jourdon P, Feuvray D. Calcium and potassium currents in ventricular myocytes isolated from diabetic rats. J Physiol. 1993;470:411-429.
12. + currents in rat ventricular myocytes. Circ Res. 1994;74:620-628.
13. 3H]PN 200-110 binding to cardiac muscle membrane in streptozotocin-induced diabetic rats. Diabetes. 1990;39: 1064-1069.
14. 2+ channel and unchanged total β-receptor number in long-term streptozotocin-diabetic rats. Eur J Endocrinol. 1996;134:107-113.
15. Nagase N, Tamura Y, Kobayashi S, Saito K, Saito M, Niki T, Chikamori K, Mori H. Myocardial disorders of hereditary diabetic KK mice. J Mol Cell Cardiol. 1981;13(suppl 2):70. Abstract.
16. Afzal N, Ganguly PK, Dhalla KS, Pierce GN, Singal PK, Dhalla NS. Beneficial effects of verapamil in diabetic cardiomyopathy. Diabetes. 1988;37:936-942.
17. Afzal N, Pierce GN, Elimban V, Beamish RE, Dhalla NS. Influence of verapamil on some subcellular defects in diabetic cardiomyopathy. Am J Physiol. 1989;256:E453-E458.
18. Fein FS, Cho S, Malhotra A, Akella J, vanHoeven KH, Sonnenblick EH, Factor SM. Beneficial effects of diltiazem on the natural history of hypertensive diabetic cardiomyopathy in rats. J Am Coll Cardiol. 1991; 18:1406-1417.
19. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky M. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 1992;15:193-203.
20. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994;331:1188-1193.
21. Schwartz S, Raskin P, Fonseca V, Graveline JF. Effects of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med. 1998;338:861-866.
22. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998;338:867-872.
23. Ren J, Dominguez LJ, Sowers JR, Davidoff AJ. Troglitazone attenuates high-glucose-induced abnormalities in relaxation and intracellular calcium in rat ventricular myocytes. Diabetes. 1996;45:1822-1825.
24. Ghazzi MN, Perez J, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Whitcomb RW, the Troglitazone Study Group. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes. 1997;46:433-439.
25. 2+ currents and not endothelial nitric oxide production. Diabetes. 1997;46:659-664.
26. Nakamura Y, Ohya Y, Onaka U, Fujii K, Abe I, Fujishima M. Inhibitory action of insulin-sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea-pig. Br J Pharmacol. 1998;123: 675-682.
27. + channels by adenosine in isolated atrial cells: involvement of GTP-binding proteins. Pflugers Arch. 1986;407:264-274.
28. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch. 1981;391:85-100.
29. Yatani A, Codina J, Imoto Y, Reeves JP, Birnbaumer L, Brown AM. A G protein directly regulates mammalian cardiac calcium channels. Science. 1987;238:1288-1292.
30. Bean BP. Two kinds of calcium channels in canine atrial cells: differences in kinetics, selectivity, and pharmacology. J Gen Physiol. 1985;86:1-30.
31. Mitra R, Morad M. Two types of calcium channels in guinea pig ventricular myocytes. Proc Natl Acad Sci U S A. 1986;83:5340-5344.
32. Cerbai E, Klockner U, Isenberg G. Ca-antagonistic effects of adenosine in guinea pig atrial cells. Am J Physiol. 1988;255:H872-H878.
33. Tytgat J, Nilius B, Vereecke J, Carmeliet E. The T-type Ca channel in guinea-pig ventricular myocytes is insensitive to isoproterenol. Pflugers Arch. 1988;411:704-706.
34. Nakajima T, Takikawa R, Sugimoto T, Kurachi Y. Effects of calcitonin gene-related peptide on membrane currents in mammalian cardiac myocytes. Pflugers Arch. 1991;419:644-650.
35. Shibata H, Nii S, Kobayashi M, Izumi T, Sasahara K, Yamaguchi K. Phase I study of a new hypoglycemic agent CS-045 in healthy volunteers: safety and pharmacokinetics in reported administration[in Japanese]. Rinsho Iyaku. 1993;9:1519-1537.
36. Wagner JA, Reynolds IJ, Weisman HF, Dudeck P, Weisfeldt ML, Snyder SH. Calcium antagonist receptors in cardiomyopathic hamster: selective increases in heart, muscle, brain. Science. 1986;232:515-518.
37. Chatterjee K, Raff G, Anderson D, William W, Parmley W. Hypertrophic cardiomyopathy: therapy with slow channel inhibiting agents. Prog Cardiovasc Dis. 1982;25:193-209.
38. Lee KS, Tsien RW. Mechanism of calcium channel blockade by verapamil, D600, diltiazem and nitrendipine in single dialysed heart cells. Nature. 1983;302:790-794.
39. Sanguinetti MC, Kass RS. Voltage-dependent block of calcium channel current in the calf cardiac Purkinje fiber by dihydropyridine calcium channel antagonists. Circ Res. 1984;55:336-348.
40. Horikoshi H, Yoshioka T, Kawasaki T, Nakamura K, Matsunuma N, Yamaguchi K, Sasahara, K. Troglitazone (CS-045), a new antidiabetic drug. Annu Rep Sankyo Res Lab. 1994;46:1-57.
41. Spedding M, Paoletti R. Classification of calcium channels and the sites of action of drugs modifying channel function. Pharmacol Rev. 1992;44: 363-376.
42. Hagiwara N, Irisawa H, Kameyama M. Contribution of two types of calcium currents to the pacemaker potentials of rabbit sino-atrial node cells. J Physiol. 1988;395:233-253.
43. 2+ current is expressed in hypertrophied adult feline left ventricular myocytes. Circ Res. 1993;73:777-782.